نتایج جستجو برای: overall response rate orr

تعداد نتایج: 2165667  

2015
Ralph G. Zinner Coleman K. Obasaju David R. Spigel Robert W. Weaver J. Thaddeus Beck David M. Waterhouse Manuel R. Modiano Borys Hrinczenko Petros G. Nikolinakos Jingyi Liu Andrew G. Koustenis Katherine B. Winfree Symantha A. Melemed Susan C. Guba Waldo I. Ortuzar Durisala Desaiah Joseph A. Treat Ramaswamy Govindan Helen J. Ross

INTRODUCTION PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). METHODS Patients ≥18 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperati...

Journal: :Cancer 2013
Francesco Leone Salvatore Artale Donatella Marino Celeste Cagnazzo Stefano Cascinu Carmine Pinto Giuseppe Fornarini Marco Tampellini Francesca Di Fabio Andrea Sartore-Bianchi Luciano De Carlis Raffaele Pugliese Lorenzo Capussotti Luisa Gioeni Salvatore Siena Massimo Aglietta

BACKGROUND Preoperative chemotherapy improves the outcome in patients with colorectal cancer with liver metastases. In the current study, the authors evaluated the activity of a conversion treatment with the combination of capecitabine plus oxaliplatin (XELOX) used in association with panitumumab in patients with unresectable, liver-only, metastatic colon cancer. METHODS Chemotherapy-naive pa...

2017
W Lv G Q Zhang A Jiao B C Zhao Y Shi B M Chen J L Zhang

Purpose. Our study analyses clinical trials and evaluates the efficacy of adding cetuximab in systematic chemotherapy for unresectable colorectal cancer liver-confined metastases patients. Materials and Methods. Search EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials for RCTs comparing chemotherapy plus cetuximab with chemotherapy alone for KRAS wild type patients with col...

2015
Ragini Kudchadkar Scott Ernst Bartosz Chmielowski Bruce G Redman Joyce Steinberg Anne Keating Fei Jie Caroline Chen Rene Gonzalez Jeffrey Weber

Survivin is a microtubule-associated protein believed to be involved in preserving cell viability and regulating tumor cell mitosis, and it is overexpressed in many primary tumor types, including melanoma. YM155 is a first-in-class survivin suppressant. The purpose of this Phase 2 study was to evaluate the 6-month progression-free survival (PFS) rate in patients with unresectable Stage III or I...

2015
Choong-kun Lee Minkyu Jung Hye Jin Choi Hye Ryun Kim Hyo Song Kim Mi Ryung Roh Joong Bae Ahn Hyun Cheol Chung Su Jin Heo Sun Young Rha Sang Joon Shin

PURPOSE There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. MATERIALS AND METHODS We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel combined with carboplatin for malignant melanoma patients who fa...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2011
P A Cassier V Moreno Garcia C Gomez-Roca D Olmos R Morales G Del Conte E Gallerani A Brunetto P Schoffski S Marsoni J H M Schellens N Penel E E Voest T R J Evans R Plummer R H Wilson J Soria J Tabernero J Verweij S B Kaye

3084 Background: Alkylating agents have a strong dose effect relationship and this concept is used for development of novel cytotoxic (CTX) drugs. However, the need to reach MTD to obtain optimal benefit with molecularly targeted agents (MTA) is controversial. In this study we aimed to evaluate the relationship between dose and efficacy in a large cohort of phase I patients (pts) with refractor...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2013
T André H Blons M Mabro B Chibaudel J-B Bachet C Tournigand M Bennamoun P Artru S Nguyen C Ebenezer N Aissat A Cayre F Penault-Llorca P Laurent-Puig A de Gramont

BACKGROUND The purpose of this study was to evaluate the combination of panitumumab and irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy (oxaliplatin, fluoropyrimidines-irinotecan and bevacizumab). PATIENTS AND METHODS KRAS status was first determined locally but subsequent validation of KRAS status and additional screenings (rare KRA...

2016
Meng Niu Duo Hong Teng-Chuang Ma Xiao-Wei Chen Jin-Hang Han Jun Sun Ke Xu

BACKGROUND A variety of targeted drug therapies in clinical trials have been proven to be effective for the treatment of hepatocellular carcinoma (HCC). Our study aims to compare the short-term and long-term efficacies of different targeted drugs in advanced hepatocellular carcinoma (AHCC) treatment using a network meta-analysis approach. METHODS PubMed, Embase, Ovid, EBSCO, and Cochrane cent...

2017
Xi-Ping Jiang Xiao-Hui Rui Cai-Xia Guo Ya-Qing Huang Qin Li Yun Xu

This study compared the short-term efficacies of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) through pair-wise and network meta-analyses (NMA). Randomized controlled trials (RCTs) identified in a comprehensive online literature search met our inclusion criteria. Direct and indirect evidence was combined to compare odds ratios (OR) and surfaces under the cum...

2013
June Koo Lee Seock-Ah Im Daewon Lee Ji-Yeon Kim Yoojoo Lim Eunyoung Lee Hyeong-Gon Moon Tae-Yong Kim Sae-Won Han Do-Youn Oh Se-Hoon Lee Wonshik Han Dong-Wan Kim Tae-You Kim Dong-Young Noh

PURPOSE Exemestane has shown good efficacy and tolerability in postmenopausal women with hormone receptor-positive metastatic breast cancer. However, clinical outcomes in Korean patients have not yet been reported. METHODS Data on 112 postmenopausal women with metastatic breast cancer were obtained retrospectively. Clinicopathological characteristics and treatment history were extracted from ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید